To hear about similar clinical trials, please enter your email below

Trial Title: Identification of New Serum Diagnostic Markers of Hepatocellular Carcinoma

NCT ID: NCT00373347

Condition: Liver Cancer

Conditions: Official terms:
Carcinoma, Hepatocellular

Study type: Observational

Overall status: Recruiting

Study design:

Time perspective: Prospective

Summary: The purpose of this study is to identify blood markers that have the ability to diagnose liver cancer with improved accuracy, so that it can be used alone or in conjunction with alpha-feto protein (AFP)

Detailed description: Liver cancer is a deadly cancer that is typically hard to diagnose and treat. The currently used blood marker for the clinical diagnosis of liver cancer is alpha-feto protein (AFP), which misses 40-60% of patients with liver cancer because it lacks sufficient specificity and sensitivity. The purpose of this study is to identify blood markers that have the ability to diagnose liver cancer with improved accuracy, so that it can be used alone or in conjunction with AFP. The aim of this study is to identify new blood markers of liver cancer that can be used to increase the rate of accurate diagnosis of this malignancy.

Criteria for eligibility:

Study pop:
Patients diagnosed with liver cancer

Sampling method: Non-Probability Sample
Criteria:
Inclusion Criteria: - Patients diagnosed with liver cancer based on biopsy or serum AFP level, associated with characteristic hypervascular liver tumors on triphasic spiral CT scan or MRI. - Patients with non-cancer liver conditions such as cirrhosis, adenoma, cholangioma, or nodular hyperplasia. - Patients with hepatitis B or hepatitis C viral infections not associated with liver cancer. Exclusion Criteria: -Patients will be excluded if, upon looking through their medical records, information required for data analysis are missing.

Gender: All

Minimum age: 18 Years

Maximum age: N/A

Healthy volunteers: No

Locations:

Facility:
Name: Stanford University School of Medicine

Address:
City: Stanford
Zip: 94305
Country: United States

Status: Recruiting

Contact:
Last name: Mei-Sze Chua

Phone: 650-724-3525
Email: mchua@stanford.edu

Contact backup:
Last name: Cancer Clinical Trials Office

Phone: (650) 498-7061

Investigator:
Last name: Samuel So
Email: Principal Investigator

Start date: November 2004

Completion date: December 2025

Lead sponsor:
Agency: Stanford University
Agency class: Other

Source: Stanford University

Record processing date: ClinicalTrials.gov processed this data on November 12, 2024

Source: ClinicalTrials.gov page: https://clinicaltrials.gov/ct2/show/NCT00373347

Login to your account

Did you forget your password?